From the first X-ray structures of myoglobin and hemoglobin that began to uncover how secondary structural elements organize into functional three-dimensional folds, to the first structure of the classical DNA double-helix, to the more recent determination of complex molecular machines, such as the ribosome and RNA polymerase, the field of structural biology has fundamentally altered how we perceive biological macromolecules. Visualization of proteins at the atomic level has allowed researchers to gain a detailed fundamental understanding of the molecular interactions and enzymatic processes essential for life, and is the foundation for hypothesis-driven structure-function research. Beyond its role in understanding biological processes, structural biology has dramatically impacted the development of new therapeutic modalities to treat human disease, including small molecule drug design and the identification of new biotherapeutics.
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Since its modest beginnings by today's standards, significant advances have been made in the field of X-ray crystallography, including production of recombinant proteins, crystallization of macromolecules, innovations in synchrotron radiation, cryo-cooling crystals, detector technology, phasing methodology, and structure refinement. These advances have greatly reduced the barriers for solving macromolecular structures, resulting in a structural biology revolution. 1 This was particularly evident where shortly after the human genome was sequenced, the National Institutes of Health founded the Protein Structure Initiative in 2000, aimed at generating structural information from the newly acquired genetic information. 2 This included identifying the majority of the unique threedimensional tertiary folds that proteins adopt. These efforts resulted in approximately 7000 depositions in the Protein Data Bank (PDB). 3 Currently, the PDB houses more than 48,000 distinct protein sequences, over 44,000 structures of human proteins, and over 11,000 structures that contain a nucleic acid component. 4 Despite these advances, we are still just scratching the surface with our structural understanding of multiprotein complexes. As such, there is a growing need to gain structural information for larger macromolecular machines that underlie important biological processes, such as transcription, DNA replication and repair, protein trafficking, and signal transduction, many of which are difficult to isolate, crystallize, and determine their structures using conventual methods in X-ray crystallography. Certainly, recent advances in cryo-electron microscopy (cryo-EM) have augmented these efforts and are now producing structures with resolutions that can accurately place the sidechains of amino acids into electron density maps. 5 While still financially limiting, cryo-EM is rapidly being implemented at an exciting pace to solve structures of macromolecular complexes, including transmembrane receptors and large multiprotein complexes, as well as the structure of viral particles. 6 Given the importance of structural biology to our understanding of biological processes and its close ties to therapeutic discovery, as well as its interdisciplinary nature, the Society's flagship journal, Experimental Biology and Medicine, has expanded its focus to include structural biology as a category of interest. The journal is now considering manuscripts that are focused on the structural aspects of macromolecules or have a structural component. To highlight the journal's new focus area, we have assembled a Thematic Review on Structural Biology that spans a broad range of topics from leading experts in their respective areas of research. The first two mini-reviews are from the Blacklow and Kovall laboratories where both have made seminal contributions towards understanding the roles and regulation of Notch signaling at the structural level. 7, 8 Seegar and Blacklow highlight recent structural advances in understanding the similarities and differences of ADAM (a disintegrin and metalloproteinase) proteins, which contain both catalytically active proteases and non-catalytic members, which play a critical role in Notch receptor activation. 7 Hall and Kovall survey the latest structure-function studies of transcription complexes that regulate Notch signaling, focusing on our understanding of coregulator complexes with CSL and how these affect transcriptional repression and activation. 8 Two additional mini-reviews from the Thompson and Hinck laboratories highlight the TGFb signaling pathway. 9,10 Goebel et al. provide a summary of our current structural understanding of TGFb ligandreceptor interactions, including a recent structure of the ternary receptor complex from an activin class ligand. 10 In addition, the review highlights recent advances in our understanding of mechanisms whereby ligands are regulated through interactions with its own prodomain and extracellular antagonists. Sun et al. focus their review on recent insights into the co-receptors betaglycan and endoglin, describing how the co-receptors have a similar domain architecture, but functionally they appear to have distinct functional mechanisms for augmenting TGFb ligand signaling.
Additional mini-reviews were provided by the Horn and Luca laboratories, which focused on the use of protein engineering strategies to augment structural studies. 11, 12 Certainly, a major bottleneck in obtaining structural information is a soluble, well-behaved protein sample that does not aggregate. Over the last 20 years, accessory-binding molecules have played an instrumental role in resolving intractable structural projects. At the forefront has been the implementation of nanobodies, or single-chain antibodies, that bind and stabilize the macromolecule of interest. Hoey et al. summarize recent advances in nanobody development and their utilization not only in structural studies but also in their broader use as therapeutics and diagnostics. 11 Ming et al. discuss the broader application of protein engineering and strategies for capturing lowaffinity macromolecular complexes. 12 While these methods are certainly more involved and time-consuming, they can be essential for trapping and visualizing low affinity protein-protein interactions.
The last three mini-reviews cover a broad range of topics. West and Deng discuss the structural advances in understanding the immune regulator receptors of the B7 and CD28 families. 13 The authors describe the structural diversity of the receptors, highlighting the complexities of targeting them during immunotherapy. Following this review, Matlahov and van der Wel discuss the structural basis of Huntington Disease and the Huntington protein. 14 This review discusses the challenges associated with understanding the pathogenic versions of this protein, which can form misfolded aggregates. Certainly, understanding the structural basis for a disease that is associated with pathogenic aggregation is complex, requiring multiple complimentary techniques, including X-ray crystallography, cryo-EM, nuclear magnetic resonance spectroscopy (NMR), and other biophysical approaches. The authors highlight the recent advances and implementation of solid-state NMR to study the large polyglutamine aggregates which are intractable by solution-based NMR methods. Finally, the review by Shurina and Page discusses how structural biology can help with rational small molecule drug design. 15 In this review, the authors discuss how up to 20 structures have been determined of different small molecules binding to carbapenemase-2, an enzyme that can inactivate b-lactam antibiotics. Collectively, these structures provide a foundation for future development of small molecule inhibitors that target b-lactamases, allowing the b-lactam drugs to remain effective.
In summary, this Thematic Review provides a small snapshot of the various disciplines that structural biology extends into and enlightens, as well as to encourage future submissions to Experimental Biology and Medicine that incorporate structural biology approaches and experimental results into their articles.
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